Brad Garcia is vice president of corporate development at Nimble Therapeutics. Brad brings more than 20 years of biotechnology and pharmaceutical experience to Nimble, where he currently leads corporate development, business operations, and finance.
Immediately before joining Nimble, he led the business development and commercialization activities for the peptide group at Roche, ultimately working to complete Nimble’s initial fundraising and spinout. Prior to Roche, Brad served in numerous scientific and business leadership roles at Agracetus (Monsanto Company), Pierce Biotechnology (Thermo Fisher Scientific), Gentel Biosciences (Intuitive Biosciences), and Primorigen Biosciences (Nucleus Biologics), and also provided business consulting services to his professional network. Brad received his undergraduate and graduate training from the University of Wisconsin, Madison, and has published in Nature Biotech, PNAS, Stem Cell Reports, among others.
Away from work, Brad enjoys traveling and spending time with family and friends, following Wisconsin Badger athletics and the Green Bay Packers (of course!), and embarking on culinary adventures.
